230 related articles for article (PubMed ID: 19128200)
21. Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats.
Ross JT; Corrigall WA; Heidbreder CA; LeSage MG
Eur J Pharmacol; 2007 Mar; 559(2-3):173-9. PubMed ID: 17303116
[TBL] [Abstract][Full Text] [Related]
22. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR
Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363
[TBL] [Abstract][Full Text] [Related]
23. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.
Pak AC; Ashby CR; Heidbreder CA; Pilla M; Gilbert J; Xi ZX; Gardner EL
Int J Neuropsychopharmacol; 2006 Oct; 9(5):585-602. PubMed ID: 16942635
[TBL] [Abstract][Full Text] [Related]
24. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
Huang M; Kwon S; Oyamada Y; Rajagopal L; Miyauchi M; Meltzer HY
Pharmacol Biochem Behav; 2015 Nov; 138():49-57. PubMed ID: 26383990
[TBL] [Abstract][Full Text] [Related]
25. Dopamine D4 receptors in psychostimulant addiction.
Di Ciano P; Grandy DK; Le Foll B
Adv Pharmacol; 2014; 69():301-21. PubMed ID: 24484981
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
27. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.
Sokoloff P; Diaz J; Le Foll B; Guillin O; Leriche L; Bezard E; Gross C
CNS Neurol Disord Drug Targets; 2006 Feb; 5(1):25-43. PubMed ID: 16613552
[TBL] [Abstract][Full Text] [Related]
28. Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine.
Salamone JD; Correa M
Behav Brain Res; 2002 Dec; 137(1-2):3-25. PubMed ID: 12445713
[TBL] [Abstract][Full Text] [Related]
29. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.
Barth V; Need AB; Tzavara ET; Giros B; Overshiner C; Gleason SD; Wade M; Johansson AM; Perry K; Nomikos GG; Witkin JM
J Pharmacol Exp Ther; 2013 Feb; 344(2):501-10. PubMed ID: 23197772
[TBL] [Abstract][Full Text] [Related]
30. Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists.
Caine SB; Negus SS; Mello NK; Patel S; Bristow L; Kulagowski J; Vallone D; Saiardi A; Borrelli E
J Neurosci; 2002 Apr; 22(7):2977-88. PubMed ID: 11923462
[TBL] [Abstract][Full Text] [Related]
31. Dopamine D2/D3 receptors play a specific role in the reversal of a learned visual discrimination in monkeys.
Lee B; Groman S; London ED; Jentsch JD
Neuropsychopharmacology; 2007 Oct; 32(10):2125-34. PubMed ID: 17299511
[TBL] [Abstract][Full Text] [Related]
32. Use of animal models to develop antiaddiction medications.
Gardner EL
Curr Psychiatry Rep; 2008 Oct; 10(5):377-84. PubMed ID: 18803910
[TBL] [Abstract][Full Text] [Related]
33. Dopamine D3 receptor ligands for the treatment of tobacco dependence.
Le Foll B; Goldberg SR; Sokoloff P
Expert Opin Investig Drugs; 2007 Jan; 16(1):45-57. PubMed ID: 17155853
[TBL] [Abstract][Full Text] [Related]
34. The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.
Engleman EA; Rodd ZA; Bell RL; Murphy JM
CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):454-67. PubMed ID: 19128203
[TBL] [Abstract][Full Text] [Related]
35. Role of Dopamine Signaling in Drug Addiction.
Chen W; Nong Z; Li Y; Huang J; Chen C; Huang L
Curr Top Med Chem; 2017; 17(21):2440-2455. PubMed ID: 28474551
[TBL] [Abstract][Full Text] [Related]
36. Dopamine D3 receptor antagonists as therapeutic agents.
Joyce JN; Millan MJ
Drug Discov Today; 2005 Jul; 10(13):917-25. PubMed ID: 15993811
[TBL] [Abstract][Full Text] [Related]
37. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
Gross G; Wicke K; Drescher KU
Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
[TBL] [Abstract][Full Text] [Related]
38. Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain.
Schwarz A; Gozzi A; Reese T; Bertani S; Crestan V; Hagan J; Heidbreder C; Bifone A
Synapse; 2004 Oct; 54(1):1-10. PubMed ID: 15300879
[TBL] [Abstract][Full Text] [Related]
39. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats.
Gál K; Gyertyán I
Drug Alcohol Depend; 2006 Jan; 81(1):63-70. PubMed ID: 16005579
[TBL] [Abstract][Full Text] [Related]
40. Dopamine D1 and D3 receptor interactions in cocaine reward and seeking in rats.
Galaj E; Harding W; Ranaldi R
Psychopharmacology (Berl); 2016 Dec; 233(23-24):3881-3890. PubMed ID: 27582181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
